According to Zhitong Finance App News, Xuantai Pharmaceutical (688247.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 191 million yuan, a year-on-year decrease of 12.95%; net profit to mother of 29.7 million yuan, a year-on-year decrease of 34.84%; net profit after deducting non-return to mother was 20.38 million yuan, a year-on-year decrease of 48.44%; and basic earnings per share were 0.07 yuan. The company plans to distribute a cash dividend of 0.15 yuan (tax included) for every 10 shares to all shareholders.

The changes in performance were mainly due to the continued promotion of procurement policies, price reductions for some products, year-on-year decline in product sales revenue, and failure to reach revenue recognition milestones during the reporting period. Revenue from the transformation of R&D technology achievements decreased by 8.5455 million yuan compared to the same period last year. The above factors led to a 12.95% year-on-year decrease in operating income, and an increase of 24.49% year-on-year in R&D expenses.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.